Rocket Pharma Is A Buy At These Prices With Promising Data

I interviewed Rocket Pharmaceuticals, Inc.’s (NASDAQ: RCKT ) CEO Dr. Gaurav Shah a year ago, but apart from that, I haven’t covered it in 2 years. My last coverage was from February 2023. Back in 2024, RCKT hadAbout the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. For investors requiring ...